When AVR is indicated: the ACC/AHA indication class framework
ACC/AHA VHD 2020 defines AVR indications in four clinical scenarios. Understanding which class applies — and why the distinction between symptomatic and asymptomatic severe AS matters — is essential before using the AS Intervention Navigator.
AVR is not indicated simply because AS is severe. The guideline framework is built around three questions: Is the AS truly severe? Are there symptoms? Are there LV changes that warrant earlier intervention? The answers determine the indication class.
Key takeaway
Symptomatic severe AS is the strongest indication for AVR (Class I). Asymptomatic severe AS only reaches Class I when LVEF is impaired. Additional Class IIa and IIb criteria apply in specific asymptomatic subgroups — but each requires additional conditions beyond severity alone.
Key points
- Class I indication (surgery strongly recommended) requires either symptomatic severe AS or asymptomatic severe AS with LVEF < 50%.
- Class IIa (surgery reasonable) includes very severe AS (Vmax ≥ 5.0 m/s), rapid progression, or abnormal exercise testing in low-risk patients.
- Class IIb (surgery may be considered) includes asymptomatic severe AS with low surgical risk and very careful shared decision-making.
- Concurrent cardiac surgery (e.g., CABG) in a patient with at least moderate AS upgrades AVR to Class I.
- Indication class and approach (TAVI vs SAVR) are separate decisions — confirm the class before selecting the approach.
When to read this
You have a patient with confirmed severe AS and want to understand what indication class applies and why — before using the AS Intervention Navigator.
AVR indication classes — ACC/AHA VHD 2020
| Class | Clinical scenario | Additional conditions | Perioperative relevance |
|---|---|---|---|
| Class I (Recommended) | Symptomatic severe AS | Any surgical risk — symptoms are the primary driver | Most common presentation referred for AVR |
| Class I (Recommended) | Asymptomatic severe AS with reduced LVEF | LVEF < 50% due to AS (not another cause) | Important to document whether LVEF reduction is AS-related |
| Class I (Recommended) | Severe or moderate AS — concomitant cardiac surgery | Patient undergoing CABG, other valve surgery, or aortic surgery | Adds AVR to planned surgery — does not require symptoms |
| Class IIa (Reasonable) | Asymptomatic severe AS — very severe gradient | Vmax ≥ 5.0 m/s — structural severity threshold | Vmax ≥ 4.0 m/s is severe; ≥ 5.0 m/s is very severe — different class |
| Class IIa (Reasonable) | Asymptomatic severe AS — rapid progression + low risk | Annual increase in Vmax ≥ 0.3 m/s/year AND low surgical risk | Both conditions must be met — rapid progression alone is not sufficient for IIa |
| Class IIa (Reasonable) | Asymptomatic severe AS — exercise test abnormal + low risk | Abnormal BP response or symptoms on exercise test AND low surgical risk | Exercise testing required — not based on rest echo alone |
| Class IIb (May be considered) | Asymptomatic severe AS — low surgical risk | Careful shared decision-making; patient preference; no other IIa triggers | Most controversial indication — requires centers with low procedural mortality |
Why the symptomatic/asymptomatic distinction matters so much
Untreated symptomatic severe AS carries very poor prognosis — median survival after symptom onset is 2–3 years without intervention. This is why symptoms are a hard driver for Class I: the benefit of AVR is clearest and most immediate. In asymptomatic patients, the natural history is better, and the trade-off between procedural risk and benefit of early intervention is more nuanced. The guidelines reflect this by requiring additional triggers (LVEF, very severe gradient, rapid progression, exercise testing) before recommending intervention in asymptomatic patients.
Approach after confirming indication
| Factor | Favors TAVI | Favors SAVR |
|---|---|---|
| Surgical risk | High or prohibitive risk | Low to intermediate risk |
| Patient age | ≥ 80 years (life expectancy consideration) | < 65 years (valve durability important) |
| Anatomy | Favorable transfemoral access | Coronary anatomy requiring re-access; bicuspid valve (relative) |
| Frailty | Frail patient — open surgery high burden | Non-frail patient tolerates recovery |
| Valve durability horizon | Limited life expectancy — durability matters less | Long life expectancy — SAVR more durable long-term |
What to confirm before advancing to intervention discussion
- Is the AS truly severe? AVA, gradient, Vmax, and DVI should be concordant — or flow state should explain discordance.
- Is the symptom status clearly established? Exertional symptoms in an older patient may be attributed to deconditioning rather than AS — exercise testing can clarify.
- Is LVEF reduction due to AS or a separate cardiomyopathy? This affects both the indication class and the expected benefit of AVR.
- Is concurrent cardiac surgery planned? This changes the threshold — moderate AS during CABG may warrant valve replacement even without symptoms.
Severe AS does not automatically equal AVR indication
A patient with AVA 0.85 cm², no symptoms, LVEF 65%, Vmax 4.2 m/s, and no rapid progression has confirmed severe AS but does not yet meet Class I or Class IIa criteria. Surveillance is the correct next step — not automatic referral. The indication class matters as much as the severity classification.
Apply this in practice
After confirming severity, evaluate AVR indication class and approach guidance in the AS Intervention Navigator.
AS Intervention Navigator